Acuta Capital Partners’s Fulcrum Therapeutics FULC Stock Holding History

Acuta Capital Partners’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-57,141	Closed	-$526K	–	33
2025 Q3	$526K	Sell	57,141 -2,509	-4%	-$18.2K	0.54%	24
2025 Q2	$410K	Buy	+59,650	New	+$319K	0.57%	24
2023 Q1	–	Sell	-185,000	Closed	-$1.35M	–	38
2022 Q4	$1.35M	Sell	185,000 -35,000	-16%	-$228K	0.83%	23
2022 Q3	$1.78M	Buy	220,000 +20,000	+10%	+$143K	0.77%	29
2022 Q2	$980K	Hold	200,000	–	–	0.55%	35
2022 Q1	$4.73M	Hold	200,000	–	–	2.21%	16
2021 Q4	$3.54M	Sell	200,000 -122,500	-38%	-$2.43M	1.49%	24
2021 Q3	$9.1M	Sell	322,500 -281,574	-47%	-$5.34M	3.21%	7
2021 Q2	$6.33M	Sell	604,074 -18,426	-3%	-$186K	2.53%	14
2021 Q1	$7.33M	Sell	622,500 -60,000	-9%	-$742K	2.64%	16
2020 Q4	$7.99M	Buy	682,500 +301,000	+79%	+$3.4M	2.17%	19
2020 Q3	$3.02M	Buy	+381,500	New	+$4.59M	0.82%	35

Other funds holding FULC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Acuta Capital Partners's FULC Position: Q4 2025 in Review

Acuta Capital Partners sold out of Fulcrum Therapeutics (FULC) in Q4 2025, closing a stake of 57,141 shares — an estimated $526K sold.

Acuta Capital Partners first reported a position in FULC in Q3 2020 and held it in 12 quarters. The position peaked at $9.1M in Q3 2021. 172 funds tracked by Wall St. Rank hold FULC as of Q4 2025.

Acuta Capital Partners reported no remaining Fulcrum Therapeutics position as of Q4 2025 after selling out during the quarter.
Acuta Capital Partners sold 57,141 Fulcrum Therapeutics shares in Q4 2025, an estimated $526K.
Acuta Capital Partners first reported a position in Fulcrum Therapeutics in Q3 2020 and held it in 12 quarters.
Acuta Capital Partners's Fulcrum Therapeutics position peaked at $9.1M in Q3 2021.
172 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2025.

Based on Acuta Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.